According to the report, one driver in market is growth of pharmaceutical industry in emerging economies.
The global pharmaceutical industry is undergoing a crisis because of the extensive use of generics, declining investments, change in the reimbursement environment, and strict government regulations on product safety and pricing.
Therefore, pharmaceutical players are exploring alternative routes to improve revenue by shifting their focus toward pharma opportunity-rich regions.
These regions are known as "pharmerging" markets owing to their high growth potential, rising GDP, increasing healthcare spending, availability of cost-efficient resources, and continuously evolving regulatory environments.
Key players in this market include Agilent Technologies, PerkinElmer, Shimadzu and Thermo Fisher Scientific.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study